S&P 500   2,746.90 (+3.29%)
DOW   23,386.11 (+3.23%)
QQQ   200.41 (+2.04%)
AAPL   265.69 (+2.41%)
FB   173.83 (+2.96%)
MSFT   165.38 (+1.16%)
GOOGL   1,209.87 (+2.31%)
AMZN   2,037.00 (+1.26%)
CGC   14.96 (+3.24%)
NVDA   266.75 (+2.98%)
BABA   195.10 (-1.46%)
MU   48.48 (+4.17%)
GE   7.30 (+3.84%)
TSLA   546.44 (+0.18%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.86 (+7.50%)
F   5.03 (+6.80%)
BAC   23.36 (+5.51%)
GILD   74.67 (+0.00%)
DIS   100.52 (-0.71%)
PRI   97.04 (+10.20%)
S&P 500   2,746.90 (+3.29%)
DOW   23,386.11 (+3.23%)
QQQ   200.41 (+2.04%)
AAPL   265.69 (+2.41%)
FB   173.83 (+2.96%)
MSFT   165.38 (+1.16%)
GOOGL   1,209.87 (+2.31%)
AMZN   2,037.00 (+1.26%)
CGC   14.96 (+3.24%)
NVDA   266.75 (+2.98%)
BABA   195.10 (-1.46%)
MU   48.48 (+4.17%)
GE   7.30 (+3.84%)
TSLA   546.44 (+0.18%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.86 (+7.50%)
F   5.03 (+6.80%)
BAC   23.36 (+5.51%)
GILD   74.67 (+0.00%)
DIS   100.52 (-0.71%)
PRI   97.04 (+10.20%)
S&P 500   2,746.90 (+3.29%)
DOW   23,386.11 (+3.23%)
QQQ   200.41 (+2.04%)
AAPL   265.69 (+2.41%)
FB   173.83 (+2.96%)
MSFT   165.38 (+1.16%)
GOOGL   1,209.87 (+2.31%)
AMZN   2,037.00 (+1.26%)
CGC   14.96 (+3.24%)
NVDA   266.75 (+2.98%)
BABA   195.10 (-1.46%)
MU   48.48 (+4.17%)
GE   7.30 (+3.84%)
TSLA   546.44 (+0.18%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.86 (+7.50%)
F   5.03 (+6.80%)
BAC   23.36 (+5.51%)
GILD   74.67 (+0.00%)
DIS   100.52 (-0.71%)
PRI   97.04 (+10.20%)
S&P 500   2,746.90 (+3.29%)
DOW   23,386.11 (+3.23%)
QQQ   200.41 (+2.04%)
AAPL   265.69 (+2.41%)
FB   173.83 (+2.96%)
MSFT   165.38 (+1.16%)
GOOGL   1,209.87 (+2.31%)
AMZN   2,037.00 (+1.26%)
CGC   14.96 (+3.24%)
NVDA   266.75 (+2.98%)
BABA   195.10 (-1.46%)
MU   48.48 (+4.17%)
GE   7.30 (+3.84%)
TSLA   546.44 (+0.18%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.86 (+7.50%)
F   5.03 (+6.80%)
BAC   23.36 (+5.51%)
GILD   74.67 (+0.00%)
DIS   100.52 (-0.71%)
PRI   97.04 (+10.20%)
Log in

NASDAQ:DMPIDelMar Pharmaceuticals Stock Price, Forecast & News

$0.49
+0.05 (+12.48 %)
(As of 04/8/2020 03:19 PM ET)
Add
Compare
Today's Range
$0.44
Now: $0.49
$0.52
50-Day Range
$0.38
MA: $0.47
$0.64
52-Week Range
$0.38
Now: $0.49
$5.75
Volume12,028 shs
Average Volume201,866 shs
Market Capitalization$5.65 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.
Read More
DelMar Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DMPI
CUSIPN/A
Phone858-350-4364

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.13) per share

Profitability

Net Income$-8,050,000.00

Miscellaneous

Employees4
Market Cap$5.65 million
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive DMPI News and Ratings via Email

Sign-up to receive the latest news and ratings for DMPI and its competitors with MarketBeat's FREE daily newsletter.


DelMar Pharmaceuticals (NASDAQ:DMPI) Frequently Asked Questions

How has DelMar Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

DelMar Pharmaceuticals' stock was trading at $0.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DMPI stock has decreased by 4.8% and is now trading at $0.4949. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DelMar Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DelMar Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DelMar Pharmaceuticals.

When is DelMar Pharmaceuticals' next earnings date?

DelMar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for DelMar Pharmaceuticals.

How were DelMar Pharmaceuticals' earnings last quarter?

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) issued its earnings results on Thursday, February, 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.03. View DelMar Pharmaceuticals' earnings history.

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

DelMar Pharmaceuticals shares reverse split on the morning of Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 7th 2019. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Has DelMar Pharmaceuticals been receiving favorable news coverage?

News headlines about DMPI stock have been trending very negative on Wednesday, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. DelMar Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutDelMar Pharmaceuticals.

Who are some of DelMar Pharmaceuticals' key competitors?

What other stocks do shareholders of DelMar Pharmaceuticals own?

Who are DelMar Pharmaceuticals' key executives?

DelMar Pharmaceuticals' management team includes the following people:
  • Mr. Saiid Zarrabian B.Sc., MBA, Pres, CEO & Director (Age 66)
  • Mr. Jeffrey A. Bacha, Founder (Age 51)
  • Dr. Dennis M. Brown, Co-Founder & Chief Scientific Officer (Age 69)
  • Mr. Scott Praill CA, CPA, BSc, CFO & Sec. (Age 52)

What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

How do I buy shares of DelMar Pharmaceuticals?

Shares of DMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DelMar Pharmaceuticals' stock price today?

One share of DMPI stock can currently be purchased for approximately $0.49.

How big of a company is DelMar Pharmaceuticals?

DelMar Pharmaceuticals has a market capitalization of $5.65 million. DelMar Pharmaceuticals employs 4 workers across the globe. View additional information about DelMar Pharmaceuticals.

What is DelMar Pharmaceuticals' official website?

The official website for DelMar Pharmaceuticals is http://www.delmarpharma.com/.

How can I contact DelMar Pharmaceuticals?

DelMar Pharmaceuticals' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-350-4364 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: Cost of Goods Sold (COGS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel